Adams M, Sionean C, Broz D, Lewis R, Wejnert C (2020) Serious mental illness among young people who inject drugs: an assessment of injection risks and healthcare use. J Infect Dis 222(Supplement_5):S401–S409. https://doi.org/10.1093/infdis/jiaa238

Alimohammadi A, Holeksa J, Thiam A, Truong D, Conway B (2018) Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs (PWID) delivered in a multidisciplinary setting. Open Forum Infect Dis 5(6):ofy120. https://doi.org/10.1093/ofid/ofy120

Alipour A (2022) Hepatitis C virus coinfection in people with human immunodeficiency virus in Iran: a systematic review and meta-analysis. Open Forum Infect Dis 9(10):1–13. https://doi.org/10.1093/ofid/ofac477

Article  Google Scholar 

Barré T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B (2020) Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). Addiction 115(3):573–582. https://doi.org/10.1111/add.14820

Article  PubMed  Google Scholar 

Bartlett SR, Wong S, Yu A, Pearce M, Macisaac J, Nouch S, Adu P, Wilton J, Samji H, Clementi E, Velasquez H, Jeong D, Binka M, Alvarez M, Wong J, Buxton J, Krajden M, Janjua N Z (2022) The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from the Direct-acting Antiviral ( DAA ) Era: a population-based study. Clin Infect Dis 74(4):575–583. https://doi.org/10.1093/cid/ciab546

Boek CE, Adesigbin C, Agwuocha C, Anartati A, Aung HT, Aung KS, Grover GS, Ngo D, Okamoto E, Ngwije A, Nsanzimana S, Sindhwani S, Singh G, Sun LP, Kinh N Van, Waworuntu W, McClure C (2020) Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination. BMJ Global Health 5(12):e003767. https://doi.org/10.1136/bmjgh-2020-003767

Bonnington O, Harris M (2017) Tensions in relation: how peer support is experienced and received in a hepatitis C treatment intervention. Int J Drug Policy 47:221–229. https://doi.org/10.1016/j.drugpo.2017.05.031

Article  PubMed  Google Scholar 

Broady TR, Brener L, Cama E, Hopwood M, Treloar C (2020) Stigmatising attitudes towards people who inject drugs, and people living with blood borne viruses or sexually transmissible infections in a representative sample of the Australian population. PLoS ONE 15(4):e0232218. https://doi.org/10.1371/journal.pone.0232218

Buchanan R, Meskarian R, van der Heijden P, Grellier L, Parkes J, Khakoo SI (2020) Prioritising hepatitis C treatment in people with multiple injecting partners maximises prevention: a real-world network study. J Infect 80(2):225–231. https://doi.org/10.1016/j.jinf.2019.12.010

Article  CAS  PubMed  Google Scholar 

Cacoub P, Comarmond C (2018) Considering hepatitis C virus infection as a systemic disease. Semin Dial 32(2):99–107. https://doi.org/10.1111/sdi.12758

Article  PubMed  Google Scholar 

Conway B, Bruneau J, Cooper C, Steingart C, Fraser C, Stewart K, Deshaies L, Thomas R, Webster D, Macphail G, Powis J, Cox J, Feld JJ, McGovern ME, Trepanier JB, Drolet M (2020) Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): a retrospective study. Can Liver J 3(4):358–371. https://doi.org/10.3138/canlivj-2020-0004

Article  PubMed  PubMed Central  Google Scholar 

Cornberg M, Manns MP (2022) The curing regimens of HCV: A SWOT analysis. Antiviral Ther 27(1–2):13596535211072672. https://doi.org/10.1177/13596535211072672

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J (2019a) Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int 39(1):20–30. https://doi.org/10.1111/liv.13949

Article  PubMed  Google Scholar 

Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU) (2019b) Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int 39(1):20–30.https://doi.org/10.1111/liv.13949

Dillon JF, Lazarus JV, Razavi HA (2016) Urgent action to fight hepatitis C in people who inject drugs in Europe. Hepatol Med Policy 1(1):2. https://doi.org/10.1186/s41124-016-0011-y

Article  PubMed  PubMed Central  Google Scholar 

ECDC (2021) Hepatitis C: annual epidemiological report for 2019. In Surveillance report (Issue June). ECDC, Stockholm

ECDC and EMCDDA (2018) Public health guidance on prevention and control of blood-borne viruses in prison settings. European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs and Drug Addiction, Stockholm and Lisbon

Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norris S (2017) Outcomes from a large 10-year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response. PLoS ONE 12(6):e0178398. https://doi.org/10.1371/journal.pone.0178398

EMCDDA (2019) Hepatitis C: new models of care for drug service (Issue July). EMCDDA, Lisbon

EMCDDA (2021) Increasing access to hepatitis C testing and care for people who inject drugs. Identifying barriers to and opportunities for supporting hepatitis C testing and care in drug services: a participatory diagnostic process. EMCDDA, Lisbon. https://doi.org/10.2810/222624

Falade-Nwulia O, Ward KM, McCormick S, Mehta SH, Pitts SR, Katz S, Chander G, Thomas DL, Sulkowski M, Latkin CA (2020) Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. J Viral Hepatitis 27(7):663–670. https://doi.org/10.1111/jvh.13274

Article  Google Scholar 

Goodyear T, Brown H, Browne AJ, Hoong P, Ti L, Knight R (2021) “Stigma is where the harm comes from”: exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. Int J Drug Policy 96:103238. https://doi.org/10.1016/j.drugpo.2021.103238

Graf C, Mücke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, Zeuzem S, Herrmann E, Vermehren J (2020) Efficacy of direct-acting antivirals for chronic hepatitis c virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis. Clin Infect Dis 70(11):2355–2365. https://doi.org/10.1093/cid/ciz696

Article  CAS  PubMed  Google Scholar 

Grebely J, Applegate TL, Cunningham P, Feld JJ (2017a) Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn 17(12):1109–1115. https://doi.org/10.1080/14737159.2017.1400385

Article  CAS  PubMed  Google Scholar 

Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, Treloar C (2017b) Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy. Int J Drug Policy 47:26–33. https://doi.org/10.1016/j.drugpo.2017.08.001

Article  PubMed  Google Scholar 

Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Dore GJ (2017c) Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy 47:51–60. https://doi.org/10.1016/j.drugpo.2017.05.019

Article  PubMed  PubMed Central  Google Scholar 

Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C (2019a) Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 72:1–10. https://doi.org/10.1016/j.drugpo.2019.07.016

Article  PubMed  Google Scholar 

Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, Vickerman P, Blach S, Cunningham E, Dumchev K, Lynskey M, Trickey A, Razavi H, Mattick RP, Farrell M, Dore GJ, Degenhardt L (2019b) Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 114(1):150–166. https://doi.org/10.1111/add.14393

Article  PubMed  Google Scholar 

Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB (2017d) Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?. J Int AIDS Soc 20(1):22146. https://doi.org/10.7448/IAS.20.1.22146

Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng C-Y, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Platt H (2022) Reinfection and risk behaviors after treatment of hepatitis C virus infection in persons receiving opioid agonist therapy. Ann Int Med 175(9):1221–1229. https://doi.org/10.7326/M21-4119

Guggisberg H, Nicca D, Kohler A, Bruggmann P, Künzler-Heule P (2022). “Shaping the new freedom”: a reflexive thematic analysis on patients’ post cure needs after years of living with hepatitis C. Swiss Med Wkly 152:w30177. https://doi.org/10.4414/SMW.2022.w30177

Harm Reduction International (2022) The global state of harm reduction 2022. Harm Reduction International, London

Jugnarain DV, Halford R, Smith S, Hickman M, Samartsidis P, Foster GR (2021) Role of peer support in a hepatitis C elimination programme. J Viral Hepatitis 29(1):43–51. https://doi.org/10.1111/jvh.13626

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB (2017) Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153(4):996.e1–1005.e1. https://doi.org/10.1053/j.gastro.2017.06.012

Article  PubMed  Google Scholar 

Karasz A, Singh R, McKee MD, Merchant K, Kim AY, Page, K, Pericot-Valverde I, Stein ES, Taylor LE, Wagner K, Litwin AH (2022) Treatment for hepatitis C virus with direct acting antiviral agents: perspectives and treatment experiences of people who inject drugs. J Subs Abuse Treat 140:108768. https://doi.org/10.1016/j.jsat.2022.108768

Krekulova L, Oktabec Z, Riley LW (2022) Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection. Int J Environ Res Public Health 19(7):4158. https://doi.org/10.3390/ijerph19074158

Larney S, Leung J, Grebely J, Hickman M, Vickerman P, Peacock A, Stone J, Trickey A, Dumchev KV, Colledge S, Cunningham EB, Lynskey M, Mattick RP, Degenhardt L (2020) Global systematic review and ecological analysis of HIV in people who inject drugs: national population sizes and factors associated with HIV prevalence. Int J Drug Policy 77:102656. https://doi.org/10.1016/j.drugpo.2019.102656

Article  PubMed  Google Scholar 

Liu S, Zhou Y, Wang Y, Li CB, Wang W, Lu X, Liu P (2022) The correlated risk factors for severe liver damage among hiv-positive inpatients with abnormal liver tests. Front Med 9:1–8. https://doi.org/10.3389/fmed.2022.817370

Article  Google Scholar 

Masarone M, Caruso R, Aglitti A, Izzo C, De Matteis G, Attianese MR, Pagano AM, Persico M (2020) Hepatitis C virus infection in jail: difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. Digest Liver Dis 52(5):541–546. https://doi.org/10.1016/j.dld.2020.02.012

Maticic M, Zorman JV, Gregorcic S, Schatz E, Lazarus JV (2019) Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. Harm Reduct J 16(1):1–13. https://doi.org/10.1186/s12954-019-0303-9

Article  Google Scholar 

Molinaro S, Resce G, Alberti A, Andreoni M, D′Egidio PPF, Leonardi C, Nava FA, Pasqualetti P, Villa S (2019) Barriers to effective management of hepatitis C virus in people who inject drugs: evidence from outpatient clinics. Drug Alcohol Rev 38(6):644–655.https://doi.org/10.1111/dar.12978

Moretta Tartaglione A, Cavacece Y, Cassia F, Russo G (2018) The excellence of patient-centered healthcare: Investigating the links between empowerment, co-creation and satisfaction. TQM J 30(2):153–167. https://doi.org/10.1108/TQM-11-2017-0138

Article  Google Scholar 

Muncan B, Walters SM, Ezell J, Ompad DC (2020) They look at us like junkies: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J 17(1):53. https://doi.org/10.1186/s12954-020-00399-8

Murdock RM, Brizzi MB, Perez O, Badowski ME (2019) Public health considerations among people who inject drugs with HIV/HCV co-infection: a review. Infect Dis Ther 8(1):23–32. https://doi.org/10.1007/s40121-018-0228-8

Article  PubMed  PubMed Central  Google Scholar 

OECD/European Union (2020) How resilient have European health systems been to the COVID-19 crisis? In: Health at a glance: Europe 2020: state of health in the EU cycle. OECD Publishing, Paris. https://doi.org/10.1787/85e4b6a1-en

Olgin GK, Bórquez A, Baker P, Clairgue E, Morales M, Bañuelos A, Arredondo J, Harvey-Vera A, Strathdee S, Beletsky L, Cepeda JA (2020) Preferences and acceptability of law enforcement initiated referrals for people who inject drugs: a mixed methods analysis. Subst Abuse Treat Prev Policy 15(1):1–9. https://doi.org/10.1186/s13011-020-00319-w

Article  Google Scholar 

Palmateer N, Hamill V, Bergenstrom A, Bloomfield H, Gordon L, Stone J, Fraser H, Seyler T, Duan Y, Tran R, Trayner K, Biggam C, Smith S, Vickerman P, Hickman M, Hutchinson S (2022) Interventions to prevent HIV and Hepatitis C among people who inject drugs: latest evidence of effectiveness from a systematic review (2011 to 2020). Int J Drug Policy 109:103872. https://doi.org/10.1016/j.drugpo.2022.103872

Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H (2018) EASL recommendations on treatment of hepatit